Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Decreases By 41.3%

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 140,400 shares, a decrease of 41.3% from the May 31st total of 239,200 shares. Based on an average daily volume of 110,200 shares, the days-to-cover ratio is presently 1.3 days. Currently, 0.7% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Brookline Capital Management raised Aileron Therapeutics to a “strong-buy” rating in a report on Thursday, May 30th. LADENBURG THALM/SH SH increased their price objective on Aileron Therapeutics from $9.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, April 18th.

Aileron Therapeutics Price Performance

NASDAQ ALRN traded down $0.04 on Friday, hitting $2.86. 10,795 shares of the stock traded hands, compared to its average volume of 75,227. The business’s fifty day moving average is $3.66 and its two-hundred day moving average is $4.31. Aileron Therapeutics has a 12 month low of $1.01 and a 12 month high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings data on Monday, May 20th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.72). Analysts anticipate that Aileron Therapeutics will post -0.93 earnings per share for the current year.

Insider Transactions at Aileron Therapeutics

In other news, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $3.25, for a total value of $30,361.50. Following the completion of the sale, the insider now directly owns 1,753,156 shares of the company’s stock, valued at $5,697,757. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $4.95, for a total value of $53,192.70. Following the completion of the transaction, the insider now directly owns 1,799,711 shares of the company’s stock, valued at $8,908,569.45. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $3.25, for a total value of $30,361.50. Following the completion of the transaction, the insider now directly owns 1,753,156 shares of the company’s stock, valued at $5,697,757. The disclosure for this sale can be found here. Insiders sold a total of 64,618 shares of company stock valued at $248,685 over the last ninety days. 5.57% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aileron Therapeutics

An institutional investor recently bought a new position in Aileron Therapeutics stock. Sigma Planning Corp purchased a new position in Aileron Therapeutics, Inc. (NASDAQ:ALRN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 16,580 shares of the company’s stock, valued at approximately $51,000. Sigma Planning Corp owned 0.34% of Aileron Therapeutics at the end of the most recent reporting period. 90.89% of the stock is currently owned by institutional investors and hedge funds.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).